These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21573021)

  • 1. Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo.
    Sasaki S; Ishida T; Toyota M; Ota A; Suzuki H; Takaoka A; Yasui H; Yamamoto H; Takagi H; Maeda M; Seito T; Tsujisaki M; Shinomura Y; Imai K
    PLoS One; 2011 May; 6(5):e19618. PubMed ID: 21573021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma.
    Wang CJ; Xiao CW; You TG; Zheng YX; Gao W; Zhou ZQ; Chen J; Xue XB; Fan J; Zhang H
    Mol Cancer; 2012 May; 11():31. PubMed ID: 22569271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
    Liu L; Qin S; Zheng Y; Han L; Zhang M; Luo N; Liu Z; Gu N; Gu X; Yin X
    Cancer Biol Ther; 2017 Mar; 18(3):166-176. PubMed ID: 28368741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.
    Wang L; Park H; Chhim S; Ding Y; Jiang W; Queen C; Kim KJ
    Mol Cancer Ther; 2012 Apr; 11(4):864-72. PubMed ID: 22351746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines.
    Murata M; Nabeshima S; Kikuchi K; Yamaji K; Furusyo N; Hayashi J
    Cytokine; 2006 Feb; 33(3):121-8. PubMed ID: 16522372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.
    Wang F; Ying HQ; He BS; Pan YQ; Deng QW; Sun HL; Chen J; Liu X; Wang SK
    Oncotarget; 2015 Apr; 6(10):7899-917. PubMed ID: 25760077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I
    Wu L; Sun B; Lin X; Liu C; Qian H; Chen L; Yang Y; Shen F; Su C
    Genes Cells; 2018 Jan; 23(1):35-45. PubMed ID: 29210217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells.
    Wei W; Chua MS; Grepper S; So SK
    Mol Cancer; 2009 Sep; 8():76. PubMed ID: 19778454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
    Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
    Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents.
    Wong NC; Cheung PF; Yip CW; Chan KF; Ng IO; Fan ST; Cheung ST
    Mol Cancer Ther; 2014 Dec; 13(12):3001-12. PubMed ID: 25253787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
    Zuo C; Qiu X; Liu N; Yang D; Xia M; Liu J; Wang X; Zhu H; Xie H; Dan H; Li Q; Wu Q; Burns M; Liu C
    Exp Cell Res; 2015 May; 333(2):316-326. PubMed ID: 25724899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization.
    Noguchi R; Yoshiji H; Ikenaka Y; Kitade M; Kaji K; Yoshi J; Yanase K; Namisaki T; Yamazaki M; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Int J Oncol; 2008 Jan; 32(1):193-9. PubMed ID: 18097559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma.
    Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
    Katsura Y; Wada H; Murakami M; Akita H; Hama N; Kawamoto K; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S517-26. PubMed ID: 23508585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma.
    Kwon S; Choi KC; Kim YE; Ha YW; Kim D; Park BK; Wu G; Kim DS; Lee Y; Kwon HJ
    Cancer Res; 2014 Jul; 74(14):3844-56. PubMed ID: 24802189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.